These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36623331)

  • 1. Identification of inhibitors as drug candidates against Chagas disease.
    Araujo SC; de Angelo RM; Barbosa H; Costa-Silva TA; Tempone AG; Lago JHG; Honorio KM
    Eur J Med Chem; 2023 Feb; 248():115074. PubMed ID: 36623331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
    da Silva EB; Oliveira E Silva DA; Oliveira AR; da Silva Mendes CH; Dos Santos TA; da Silva AC; de Castro MC; Ferreira RS; Moreira DR; Cardoso MV; de Simone CA; Pereira VR; Leite AC
    Eur J Med Chem; 2017 Apr; 130():39-50. PubMed ID: 28242550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
    Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
    Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
    de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
    Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design aided by random forests and synthesis of potent trypanocidal agents as cruzain inhibitors for Chagas disease treatment.
    de Albuquerque S; Cianni L; de Vita D; Duque C; Gomes ASM; Gomes P; Laughton C; Leitão A; Montanari CA; Montanari R; Ribeiro JFR; da Silva JS; Teixeira C
    Chem Biol Drug Des; 2020 Sep; 96(3):948-960. PubMed ID: 33058457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors.
    Maluf FV; Andricopulo AD; Oliva G; Guido RV
    Future Med Chem; 2013 Nov; 5(17):2019-35. PubMed ID: 24215344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.
    Soeiro Mde N; Dantas AP; Daliry A; Silva CF; Batista DG; de Souza EM; Oliveira GM; Salomão K; Batista MM; Pacheco MG; Silva PB; Santa-Rita RM; Barreto RF; Boykin DW; Castro SL
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():301-10. PubMed ID: 19753489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
    Ogindo CO; Khraiwesh MH; George M; Brandy Y; Brandy N; Gugssa A; Ashraf M; Abbas M; Southerland WM; Lee CM; Bakare O; Fang Y
    Bioorg Med Chem; 2016 Aug; 24(16):3849-55. PubMed ID: 27345756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico identification of inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using ligand and structure based approaches.
    de V C Sinatti V; R Baptista LP; Alves-Ferreira M; Dardenne L; Hermínio Martins da Silva J; Guimarães AC
    J Mol Graph Model; 2017 Oct; 77():168-180. PubMed ID: 28865321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cruzain inhibitors for the treatment of Chagas' disease.
    Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
    Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
    Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
    BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
    Menna-Barreto RF; de Castro SL
    Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Lack of Translation from Cruzain Inhibition to Trypanosoma cruzi Activity with Machine Learning and Chemical Space Analyses.
    Lameiro RF; Montanari CA
    ChemMedChem; 2023 Mar; 18(6):e202200434. PubMed ID: 36692246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
    Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chagas Disease and Coumarins: A Review of Natural and Synthetic Coumarins As Anti-Trypanosoma Cruzi Agents.
    Gonçalves GA; Cerecetto H; Poser GLV; Canto RFS; Eifler-Lima VL
    Mini Rev Med Chem; 2021; 21(13):1701-1717. PubMed ID: 33372872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo experimental models for drug screening and development for Chagas disease.
    Romanha AJ; Castro SL; Soeiro Mde N; Lannes-Vieira J; Ribeiro I; Talvani A; Bourdin B; Blum B; Olivieri B; Zani C; Spadafora C; Chiari E; Chatelain E; Chaves G; Calzada JE; Bustamante JM; Freitas-Junior LH; Romero LI; Bahia MT; Lotrowska M; Soares M; Andrade SG; Armstrong T; Degrave W; Andrade Zde A
    Mem Inst Oswaldo Cruz; 2010 Mar; 105(2):233-8. PubMed ID: 20428688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential of Secondary Metabolites from Plants as Drugs or Leads against
    Barbosa H; Thevenard F; Quero Reimão J; Tempone AG; Honorio KM; Lago JHG
    Curr Top Med Chem; 2023; 23(3):159-213. PubMed ID: 36515019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead identification to clinical candidate selection: drugs for Chagas disease.
    Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
    J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
    Magalhaes Moreira DR; de Oliveira AD; Teixeira de Moraes Gomes PA; de Simone CA; Villela FS; Ferreira RS; da Silva AC; dos Santos TA; Brelaz de Castro MC; Pereira VR; Leite AC
    Eur J Med Chem; 2014 Mar; 75():467-78. PubMed ID: 24561675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.